drugset / Trial / NCT00472797
Rebif New Formulation (RNF) Quality of Life (QOL) Study
RandomizedParallel-groupOpen-labelSupportive care
Summary
To evaluate the impact on Quality of Life (QOL), tolerability, treatment satisfaction, and injection site redness Rebif treated subjects with relapsing forms of MS who transition to a new formulation of Rebif (RNF).
Timeline
- Start
- 2007-04
- Primary completion
- 2009-02
- Completion
- 2009-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Interferon beta-1a | Protein / enzyme biologic | — | — |